We're reaching out to share an important update on Oxbryta® (voxelotor)*, as part of our ongoing commitment to keeping the sickle cell community informed. In April, we shared that Pfizer was continuing discussions with the U.S. Food and Drug Administration (FDA) to potentially make Oxbryta available again for people living with sickle cell. Over the past two years, Pfizer comprehensively analyzed the totality of the final clinical trial, registry (real world), and post-marketing safety and...

Scholarships will be awarded to applicants with sickle cell who present the best combination of a creative and persuasive essay, excellent recommendations, and superior academic standing. The application is open to all eligible students (inclusions/exclusions noted above). Applicants need not be on a Pfizer product to apply. Treatment regimen will have no bearing on application eligibility nor will it impact the scholarship selection process, as awardees will be chosen by an independent...